Bal Pharma Q2 Results 2026: PAT ₹1 Cr, Revenue ₹90 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹90Cr
- Net profit
- ₹1Cr
- Margin
- 9.6%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Bal Pharma Ltd Q2 FY27 key numbers
- Revenue
- Standalone revenue from operations for the same quarter: ₹8,971.99 lakhs, up from ₹7,374.95 lakhs year-on-year (~21.6% growth).
As stated in Bal Pharma Ltd's Q2 FY27 results statement · published 11 Nov 2026. Reported figures, not investment advice.
Based on Bal Pharma Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of ₹1,592.20 lakhs (~21.5% growth).
From Bal Pharma Ltd's Q2 FY27 earnings-call transcript · updated 11 Nov 2026.
How did Bal Pharma's revenue grow in the September 2026 quarter?
- Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of ₹1,592.20 lakhs (~21.5% growth).
- Standalone revenue from operations for the same quarter: ₹8,971.99 lakhs, up from ₹7,374.95 lakhs year-on-year (~21.6% growth).
What happened to Bal Pharma's margins in Q2 FY27?
See what Bal Pharma Ltd said on profitability & margins — free account, 30 seconds.
What capex is Bal Pharma planning?
- Greenfield API Manufacturing Facility at Yadgiri, Karnataka:
- Original allocation: ₹8.40 crore
- Status as of September 30, 2026: No funds utilized yet; ₹2.10 crore received from preferential issue remain unutilized.
- Capital Work-in-Progress noted in Balance Sheets:
- ₹238.23 lakh (Standalone, Sep 30, 2026) down from ₹742.42 lakh (March 31, 2026), indicating ongoing capital expenditure activities.
2 more points from Bal Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Bal Pharma raising money or cutting debt?
See what Bal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Bal Pharma's order book?
See what Bal Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Bal Pharma Ltd — Quarterly revenue & net profit
Bal Pharma Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 90 |
| Operating profit (EBITDA) | 9 |
| Operating margin | 9.6% |
| Profit before tax | 2 |
| Net profit (PAT) | 1 |
| EPS (₹) | 0.89 |
Source: Bal Pharma Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsRevenue ₹3770 Cr · PAT ₹1,127 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Bafna Pharmaceuticals (Q2 FY27)
INR 3,546.82 Lakhs, approximately 34.4% increase. Key results statement takeaways from Bafna Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks
- Quest Laboratories (Q2 FY27)
Revenue from operations for the half year ended 30th September 2026 is ₹5,533.55 lakhs, compared to ₹4,880.48 lakhs for the half year ended 30th September…
- Haleos Labs Limited (Q2 FY27)
1,036.03 Lakhs (~13.3% growth). Key results statement takeaways from Haleos Labs Limited's Q2 FY27 results statement — and how it ranks against sector peers.
- Curis Lifesciences (Q2 FY27)
2790.89 lakh for the quarter ended 30.09.2025 (standalone), indicating a year-on-year increase of approximately 32.8%. Key results statement takeaways from Curi
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bal Pharma Ltd Q2 FY27 results?
Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of ₹1,592.20 lakhs (~21.5% growth).
What is Bal Pharma Ltd share price analysis?
Bal Pharma Ltd currently shows a neutral. The stock trades at a P/E of 18.4 with a market cap of ₹132 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bal Pharma Ltd planning capital expenditure?
Greenfield API Manufacturing Facility at Yadgiri, Karnataka:.
Keep Bal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.